In this article, we will look at the 12 Oversold Blue Chip Stocks to Buy According to Analysts.
Oversold blue chip stocks are drawing a closer look, but not just because they have fallen. After a strong run in equities, the easier gains from multiple expansion appear harder to come by, shifting attention back to entry points, valuation discipline, and stock selection. That matters even more when large, established companies have been sold off despite analysts still holding a constructive view on the underlying business. In this kind of market, the real question is not whether weakness alone makes a stock attractive, but whether the pullback has created a better setup in blue chip names that the market may have grown too pessimistic on.
That is broadly the message in the institutional commentary. J.P. Morgan Asset Management says “High quality stocks are now priced at a discount,” adding that within U.S. markets, the quality factor is “more attractive than ever” outside unusually dislocated periods. Fidelity makes a similar point from the stock-picking side, saying “Market pullbacks can provide windows of opportunity” to buy quality stocks at “temporarily marked-down prices.” Putnam adds the large-cap angle, noting that while the S&P 500 is “more expensive than average,” “many in this cohort are trading in line with or cheaper than their historical averages.” The index may still look expensive, but parts of the blue-chip universe have already been repriced.
Against this backdrop, oversold blue chips that still carry bullish analyst views start to stand out. That brings us to the 12 Oversold Blue Chip Stocks to Buy According to Analysts.
Our Methodology
We used the Finviz screener to identify blue chip stocks with an RSI reading of less than 30, and then filtered for those offering meaningful upside based on analysts’ median price targets. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
12. Colgate-Palmolive Company (NYSE:CL)
On April 10, 2026, BofA analyst Peter Galbo lowered the price target on Colgate-Palmolive Company (NYSE:CL) to $102 from $105 and maintained a Buy rating ahead of Q1 results. Peter Galbo said the firm updated its estimates for organic sales and FY26 EPS to reflect delayed launch timing for Optic White in North America, which impacts near-term consumption, as well as a more conservative view on gross margins given rising oil-related input costs.
On April 9, 2026, RBC Capital lowered its price target on Colgate-Palmolive Company (NYSE:CL) to $102 from $104 and maintained an Outperform rating as part of a broader Q1 preview across consumer staples. RBC said the March quarter is expected to be stable but still characterized by a sluggish top-line environment, with investor focus shifting to forward guidance amid inflationary pressures and lingering effects from the Middle East conflict, despite the recent ceasefire.
Last month, Colgate-Palmolive Company (NYSE:CL) announced that Christopher Boerner, CEO of Bristol-Myers Squibb, has been elected to its board of directors.
Colgate-Palmolive Company (NYSE:CL) manufactures and sells consumer products globally.
11. Insulet Corporation (NASDAQ:PODD)
On April 13, 2026, BTIG lowered the price target on Insulet Corporation (NASDAQ:PODD) to $320 from $380 and maintained a Buy rating as part of a broader medical technology update. BTIG said it adjusted its model following CMS’ proposed FY27 inpatient prospective payment system rule, which includes commentary and decisions on new technology add-on payments.
On April 7, 2026, Citi downgraded Insulet Corporation (NASDAQ:PODD) to Neutral from Buy with a price target of $230, down from $338, ahead of the Q1 report. Citi cited increasing competition in the patch pump market, noting that new product launches in 2027 could limit share outperformance.
Meanwhile, on April 6, 2026, Evercore ISI lowered its price target on Insulet Corporation (NASDAQ:PODD) to $240 from $340 previously and maintained an Outperform rating as part of its Q1 preview for medical technology and life science tools.
Insulet Corporation (NASDAQ:PODD) develops and sells insulin delivery systems for diabetes patients.
